These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 21817854)
61. A pilot clinical trial of a near-infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking. Gelfand JA; Nazarian RM; Kashiwagi S; Brauns T; Martin B; Kimizuka Y; Korek S; Botvinick E; Elkins K; Thomas L; Locascio J; Parry B; Kelly KM; Poznansky MC FASEB J; 2019 Feb; 33(2):3074-3081. PubMed ID: 30192655 [TBL] [Abstract][Full Text] [Related]
62. Overcoming or circumventing the stratum corneum barrier for efficient transcutaneous immunization. Chen Z; Lv Y; Qi J; Zhu Q; Lu Y; Wu W Drug Discov Today; 2018 Jan; 23(1):181-186. PubMed ID: 28988995 [TBL] [Abstract][Full Text] [Related]
63. Transcutaneous vaccines--current and emerging strategies. Hirobe S; Okada N; Nakagawa S Expert Opin Drug Deliv; 2013 Apr; 10(4):485-98. PubMed ID: 23316778 [TBL] [Abstract][Full Text] [Related]
64. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. Vogt A; Combadiere B; Hadam S; Stieler KM; Lademann J; Schaefer H; Autran B; Sterry W; Blume-Peytavi U J Invest Dermatol; 2006 Jun; 126(6):1316-22. PubMed ID: 16614727 [TBL] [Abstract][Full Text] [Related]
65. Hair follicle targeting, penetration enhancement and Langerhans cell activation make cyanoacrylate skin surface stripping a promising delivery technique for transcutaneous immunization with large molecules and particle-based vaccines. Vogt A; Hadam S; Deckert I; Schmidt J; Stroux A; Afraz Z; Rancan F; Lademann J; Combadiere B; Blume-Peytavi U Exp Dermatol; 2015 Jan; 24(1):73-5. PubMed ID: 25382068 [TBL] [Abstract][Full Text] [Related]
66. Dynamic visualization of dendritic cell-antigen interactions in the skin following transcutaneous immunization. Rattanapak T; Birchall JC; Young K; Kubo A; Fujimori S; Ishii M; Hook S PLoS One; 2014; 9(2):e89503. PubMed ID: 24586830 [TBL] [Abstract][Full Text] [Related]
67. Echographic measurement of skin thickness in sites suitable for intradermal vaccine injection in infants and children. Ploin D; Schwarzenbach F; Dubray C; Nicolas JF; Goujon C; Trong MD; Laurent PE Vaccine; 2011 Oct; 29(46):8438-42. PubMed ID: 21821081 [TBL] [Abstract][Full Text] [Related]
68. [From basic principles to clinical applications on transcutaneous vaccine]. Okada N Yakugaku Zasshi; 2013; 133(12):1363-72. PubMed ID: 24292185 [TBL] [Abstract][Full Text] [Related]
69. Opportunities and challenges of the pulmonary route for vaccination. Blank F; Stumbles P; von Garnier C Expert Opin Drug Deliv; 2011 May; 8(5):547-63. PubMed ID: 21438741 [TBL] [Abstract][Full Text] [Related]
70. Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. Scheiblhofer S; Thalhamer J; Weiss R Expert Opin Drug Deliv; 2013 Jun; 10(6):761-73. PubMed ID: 23425032 [TBL] [Abstract][Full Text] [Related]
73. A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC vaccine. Gutiérrez RL; Porter CK; Jarell A; Alcala A; Riddle MS; Turiansky GW Vaccine; 2020 May; 38(21):3773-3779. PubMed ID: 32253098 [TBL] [Abstract][Full Text] [Related]
79. [Development of an Immune Regulation Technology Targeting the Skin and Promotion of the Practical Applications of Transcutaneous Vaccination/Immunotherapy]. Okada N Yakugaku Zasshi; 2019; 139(9):1129-1137. PubMed ID: 31474627 [TBL] [Abstract][Full Text] [Related]